Evaluation of Total and IgA-Specific Antibody Targeting Epstein-Barr Virus Glycoprotein 350 and Nasopharyngeal Carcinoma Risk. (28th April 2018)

• Record Type: Journal Article
• Authors: Coghill, Anna E; Bu, Wei; Hsu, Wan-Lun; Nguyen, Hanh; Yu, Kelly J; Chien, Yin-Chu; Chen, Chien-Jen; Cohen, Jeffrey I; Hildesheim, Allan
• Is Part Of: Journal of infectious diseases. Volume 218:Number 6(2018)
• Page Start: 886
• Page End: 891
• Publication Date: 2018-04-28
• Subjects: Epstein-Barr virus -- gp350 antibody -- NPC -- EBV-related cancer -- EBV vaccine; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiy250
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract : Elevated levels of total EBVgp350 antibody were not protective against future nasopharyngeal carcinoma (NPC) risk in a general population cohort from Taiwan, failing to replicate prior findings among individuals with a strong family history of NPC. Abstract: Background: We previously reported that higher levels of antibody targeting Epstein-Barr virus (EBV) glycoprotein350 (gp350), an EBV vaccine candidate, were protective against nasopharyngeal carcinoma (NPC) in genetically high-risk families from Taiwan. The current study attempted to extend this association to a general population cohort. Methods: We compared total and IgA-specific gp350 antibody levels in 35 incident NPC cases and 81 disease-free controls from the Cancer Screening Program in Taiwan (23943 individuals recruited 1991–1992). Luciferase immunoprecipitation assays quantified gp350 antibody. Results: Total EBVgp350 antibody levels were not higher in individuals who remained disease free compared to those who developed NPC ( P = .11). This lack of a protective gp350 association persisted for cases diagnosed ≥5 years (odds ratio [OR] = 1.05; P = .91) and <5 years (OR = 1.85; P = .40) after blood draw. IgA-specific gp350 antibody levels were higher in cases than controls (OR = 7.03; P = .001). This increased risk was most pronounced for cases diagnosed <5 years after blood draw (OR = 11.7; P = .004). Conclusion: Unlike our prior findings in those with a strong family history of NPC, total gp350 antibody levels were not protective against NPC development in this general population setting.